AU2022248735A1 - Anti-nectin-4 antibody exatecan conjugates - Google Patents

Anti-nectin-4 antibody exatecan conjugates Download PDF

Info

Publication number
AU2022248735A1
AU2022248735A1 AU2022248735A AU2022248735A AU2022248735A1 AU 2022248735 A1 AU2022248735 A1 AU 2022248735A1 AU 2022248735 A AU2022248735 A AU 2022248735A AU 2022248735 A AU2022248735 A AU 2022248735A AU 2022248735 A1 AU2022248735 A1 AU 2022248735A1
Authority
AU
Australia
Prior art keywords
cdr
seq
amino acid
antibody
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022248735A
Other languages
English (en)
Inventor
Jack Elands
Florence LHOSPPICE
Marc Lopez
Daniel Olive
Xavier PRÉVILLE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aix Marseille Universite
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Jean Paoli and Irene Calmettes
Eli Lilly and Co
Original Assignee
Aix Marseille Universite
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Jean Paoli and Irene Calmettes
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21170941.5A external-priority patent/EP4066899A1/en
Priority claimed from EP21172723.5A external-priority patent/EP4086284A1/en
Application filed by Aix Marseille Universite, Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Institut Jean Paoli and Irene Calmettes, Eli Lilly and Co filed Critical Aix Marseille Universite
Publication of AU2022248735A1 publication Critical patent/AU2022248735A1/en
Assigned to CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'AIX-MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES, EMERGENCE THERAPEUTICS GMBH reassignment CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS Amend patent request/document other than specification (104) Assignors: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS, EMERGENCE THERAPEUTICS GMBH, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE
Assigned to CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'AIX-MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES, ELI LILLY AND COMPANY reassignment CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS Request for Assignment Assignors: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS, EMERGENCE THERAPEUTICS GMBH, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2022248735A 2021-03-31 2022-03-31 Anti-nectin-4 antibody exatecan conjugates Pending AU2022248735A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP21166441.2 2021-03-31
EP21166441 2021-03-31
EP21170941.5 2021-04-28
EP21170941.5A EP4066899A1 (en) 2021-03-31 2021-04-28 Anti-nectin-4 antibody
EP21172723.5 2021-05-07
EP21172723.5A EP4086284A1 (en) 2021-05-07 2021-05-07 Anti-nectin-4 antibody exatecan conjugates
EP21209332 2021-11-19
EP21209332.2 2021-11-19
PCT/EP2022/058629 WO2022207825A1 (en) 2021-03-31 2022-03-31 Anti-nectin-4 antibody exatecan conjugates

Publications (1)

Publication Number Publication Date
AU2022248735A1 true AU2022248735A1 (en) 2023-08-03

Family

ID=80999114

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2022248735A Pending AU2022248735A1 (en) 2021-03-31 2022-03-31 Anti-nectin-4 antibody exatecan conjugates
AU2022250867A Pending AU2022250867A1 (en) 2021-03-31 2022-03-31 Anti-nectin-4-antibodies and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022250867A Pending AU2022250867A1 (en) 2021-03-31 2022-03-31 Anti-nectin-4-antibodies and uses thereof

Country Status (18)

Country Link
US (4) US20240181075A1 (https=)
EP (2) EP4314057A1 (https=)
JP (2) JP7579991B2 (https=)
KR (2) KR20240035378A (https=)
AU (2) AU2022248735A1 (https=)
BR (1) BR112023017728A2 (https=)
CA (2) CA3212651A1 (https=)
CL (2) CL2023002909A1 (https=)
CO (2) CO2023012821A2 (https=)
CR (2) CR20230470A (https=)
DO (2) DOP2023000213A (https=)
EC (2) ECSP23073625A (https=)
IL (2) IL305951A (https=)
JO (2) JOP20230239A1 (https=)
MX (2) MX2023011563A (https=)
PE (2) PE20240724A1 (https=)
SA (1) SA523450918B1 (https=)
WO (3) WO2022207828A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4285935A1 (en) * 2022-06-03 2023-12-06 Emergence Therapeutics AG Novel anti-nectin-4 antibody camptothecin derivative conjugates
EP4309676A1 (en) * 2022-07-22 2024-01-24 Emergence Therapeutics AG Novel anti-nectin-4 antibody camptothecin derivative conjugates
EP4344707A1 (en) * 2022-09-29 2024-04-03 Emergence Therapeutics AG New anti-nectin-4 antibody drug conjugates
EP4461317A1 (en) * 2023-05-12 2024-11-13 Emergence Therapeutics GmbH Antibody-drug conjugates comprising an anti-nectin-4 antibody and belotecan or a derivative thereof
WO2024251260A1 (zh) * 2023-06-08 2024-12-12 江苏迈威康新药研发有限公司 结合Nectin-4的抗体及其用途
JP7689606B2 (ja) * 2023-06-20 2025-06-06 イーライ リリー アンド カンパニー ネクチン－４抗体及び抗体－薬物コンジュゲート
EP4534101A1 (en) 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
EP4534102A1 (en) 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX347954B (es) 2010-09-29 2017-05-19 Agensys Inc Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12.
EP3347048B1 (en) * 2015-09-09 2020-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
CA3044898C (en) * 2016-11-25 2022-04-05 Mabwell (shanghai) Bioscience Co., Ltd. Di-substituted maleic amide linker for antibody-drug conjugating and preparation method and use thereof
CN110392697A (zh) 2017-03-02 2019-10-29 国家医疗保健研究所 对nectin-4具有特异性的抗体及其用途
JP7381478B2 (ja) * 2017-10-23 2023-11-15 マブリンク ビオシオンス 単一分子量ポリサルコシンを含むリガンド－薬物－複合体
NZ781538A (en) * 2019-04-24 2025-12-19 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
US12398206B2 (en) * 2019-10-07 2025-08-26 Université D'aixmarseille Antibodies having specificity for nectin-4 and uses thereof
WO2021143741A1 (zh) * 2020-01-15 2021-07-22 北京海步医药科技有限公司 靶向多肽-药物缀合物及其用途
EP4096717B1 (en) * 2020-01-31 2024-12-11 Innate Pharma Treatment of cancer

Also Published As

Publication number Publication date
JOP20230238A1 (ar) 2023-09-28
CR20230469A (es) 2023-11-30
PE20240724A1 (es) 2024-04-15
IL305954A (en) 2023-11-01
CA3212651A1 (en) 2022-10-06
EP4314057A1 (en) 2024-02-07
JP2024520188A (ja) 2024-05-22
KR20240028330A (ko) 2024-03-05
IL305951A (en) 2023-11-01
CR20230470A (es) 2023-11-30
MX2023011561A (es) 2024-02-08
JP2024515536A (ja) 2024-04-10
JOP20230239A1 (ar) 2023-09-28
ECSP23073436A (es) 2024-02-29
CO2023012828A2 (es) 2024-02-15
CL2023002907A1 (es) 2024-05-10
AU2022250867A1 (en) 2023-08-03
US20240034791A1 (en) 2024-02-01
US20240173424A1 (en) 2024-05-30
DOP2023000213A (es) 2024-04-30
ECSP23073625A (es) 2024-02-29
KR20240035378A (ko) 2024-03-15
CL2023002909A1 (es) 2024-05-10
WO2022207822A1 (en) 2022-10-06
BR112023019749A2 (pt) 2024-01-23
CA3212655A1 (en) 2022-10-06
JP7579990B2 (ja) 2024-11-08
CO2023012821A2 (es) 2024-02-26
US20240181075A1 (en) 2024-06-06
MX2023011563A (es) 2024-02-08
US20250018053A1 (en) 2025-01-16
WO2022207825A1 (en) 2022-10-06
JP7579991B2 (ja) 2024-11-08
US12049500B2 (en) 2024-07-30
EP4262988A1 (en) 2023-10-25
DOP2023000214A (es) 2024-04-30
WO2022207828A1 (en) 2022-10-06
PE20240725A1 (es) 2024-04-15
BR112023017728A2 (pt) 2023-11-21
SA523450918B1 (ar) 2025-05-07

Similar Documents

Publication Publication Date Title
US20240173424A1 (en) Anti-nectin-4-antibody exatecan conjugates
EP4039706A1 (en) Cldn18.2-targeting antibody, preparation method therefor, and use thereof
KR20230124037A (ko) 종양 특이적 claudin 18.2 항체-약물 접합체
EP4066899A1 (en) Anti-nectin-4 antibody
CN109320612A (zh) 抗her2抗体及其缀合物
EP4086284A1 (en) Anti-nectin-4 antibody exatecan conjugates
US20260062481A1 (en) Novel anti-nectin-4 antibodies and antibody-drug conjugates
EP4324849A1 (en) Humanized anti-nectin-4 antibodies
CN117751139A (zh) 抗Nectin-4抗体依喜替康缀合物
EP4309676A1 (en) Novel anti-nectin-4 antibody camptothecin derivative conjugates
EP4285935A1 (en) Novel anti-nectin-4 antibody camptothecin derivative conjugates
TW201922796A (zh) 可用於實體腫瘤治療之抗體及其抗體－藥物共軛物以及含其之抗癌劑
EA049994B1 (ru) Конъюгаты антитела против нектина-4 и эксатекана
BR112023019749B1 (pt) Conjugados de exatecano anti-nectina-4, composição farmacêutica que os compreende e seus usos
EA050098B1 (ru) Антитела к нектину-4 и их применение
EP4461317A1 (en) Antibody-drug conjugates comprising an anti-nectin-4 antibody and belotecan or a derivative thereof
KR20260038271A (ko) 항-trop2 항체
WO2025140511A1 (zh) 抗原结合分子、其药物偶联物及其医药用途
WO2025163468A1 (en) Anti-pd-l1 antibodies and antibody-drug conjugates and their use in the treatment of cancer
HK40045878B (zh) Igf-1r抗体及其作为定位载体用於治疗癌症的用途

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: INSTITUT JEAN PAOLI & IRENE CALMETTES

Free format text: FORMER NAME(S): EMERGENCE THERAPEUTICS GMBH; UNIVERSITE D'AIX-MARSEILLE; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS; INSTITUT JEAN PAOLI & IRENE CALMETTES

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS

Free format text: FORMER NAME(S): EMERGENCE THERAPEUTICS GMBH; UNIVERSITE D'AIX-MARSEILLE; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS; INSTITUT JEAN PAOLI & IRENE CALMETTES

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Free format text: FORMER NAME(S): EMERGENCE THERAPEUTICS GMBH; UNIVERSITE D'AIX-MARSEILLE; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS; INSTITUT JEAN PAOLI & IRENE CALMETTES

Owner name: UNIVERSITE D'AIX-MARSEILLE

Free format text: FORMER NAME(S): EMERGENCE THERAPEUTICS GMBH; UNIVERSITE D'AIX-MARSEILLE; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS; INSTITUT JEAN PAOLI & IRENE CALMETTES

Owner name: EMERGENCE THERAPEUTICS GMBH

Free format text: FORMER NAME(S): EMERGENCE THERAPEUTICS GMBH; UNIVERSITE D'AIX-MARSEILLE; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS; INSTITUT JEAN PAOLI & IRENE CALMETTES

PC1 Assignment before grant (sect. 113)

Owner name: INSTITUT JEAN PAOLI & IRENE CALMETTES

Free format text: FORMER APPLICANT(S): EMERGENCE THERAPEUTICS GMBH; UNIVERSITE D'AIX-MARSEILLE; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS; INSTITUT JEAN PAOLI & IRENE CALMETTES

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS

Free format text: FORMER APPLICANT(S): EMERGENCE THERAPEUTICS GMBH; UNIVERSITE D'AIX-MARSEILLE; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS; INSTITUT JEAN PAOLI & IRENE CALMETTES

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Free format text: FORMER APPLICANT(S): EMERGENCE THERAPEUTICS GMBH; UNIVERSITE D'AIX-MARSEILLE; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS; INSTITUT JEAN PAOLI & IRENE CALMETTES

Owner name: UNIVERSITE D'AIX-MARSEILLE

Free format text: FORMER APPLICANT(S): EMERGENCE THERAPEUTICS GMBH; UNIVERSITE D'AIX-MARSEILLE; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS; INSTITUT JEAN PAOLI & IRENE CALMETTES

Owner name: ELI LILLY AND COMPANY

Free format text: FORMER APPLICANT(S): EMERGENCE THERAPEUTICS GMBH; UNIVERSITE D'AIX-MARSEILLE; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS; INSTITUT JEAN PAOLI & IRENE CALMETTES